Mira Pharmaceuticals Inc (MIRA) — Titan Protect Analysis

MIRA

Mira Pharmaceuticals Inc

Healthcare · ·

$1.00

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$43M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-2.49

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-184.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About Mira Pharmaceuticals Inc

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognit

https://mirapharmaceuticals.com

Country: United States Industry: Drug Manufacturers - General

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.619

Good returns relative to risk taken

Kelly Fraction

0.1136

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.199

Drawdown risk outweighs the returns — higher risk profile

Annual Return

16.7%

Historical annualised return based on price data

Max Drawdown

-84.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$2.45

59% below the year high

52W Low

$0.90

11% above the year low

Avg Volume

156,561

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.27

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$339,002

Positive — the business generates more cash than it spends

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-31,365,680

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go